Hematology parameter
Showing 1 - 25 of 2,177
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Completed
- Sepsis
- +3 more
- Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)
-
Hackensack, New JerseyHackensack University Medical Center
Jul 15, 2022
Simple Endpoint Study - Indiana University Hospital
Completed
- Sepsis
- +3 more
- CBC-DIFF Monocyte Volume Width Distribution (MDW)
-
Indianapolis, IndianaIndiana University Methodist Hospital
Jul 15, 2022
COVID-19 Trial in Makassar (Vitamin D3 10000 IU, Vitamin D3 1000 IU)
Completed
- COVID-19
- Vitamin D3 10000 IU
- Vitamin D3 1000 IU
-
Makassar, South Sulawesi, IndonesiaWahidin Sudirohusodo General Hospital
Nov 17, 2021
Potential Reduction of Time to Antibiotics - Washington
Completed
- Sepsis
- +3 more
- CBC-DIFF Monocyte Volume Width Distribution (MDW)
-
Saint Louis, MissouriWashington University
Mar 15, 2021
Potential Reduction of Time to Antibiotics - Baylor S&W
Completed
- Sepsis
- +3 more
- CBC-DIFF Monocyte Volume Width Distribution (MDW)
-
Temple, TexasBaylor Scott & White MEdical Center
Jan 26, 2021
Multimodal MR Imaging in Cognitive Assessment of Moderate
Recruiting
- Brain Injuries
- Glasgow coma scale
-
Xi'an, Shaanxi, ChinaThe First Affiliated Hospital of Xi'an Jiaotong University
Oct 19, 2023
HIV Trial (Cabotegravir IR Formulation (reference), Cabotegravir DT Formulation (test 1), Cabotegravir DT Formulation (test 2))
Not yet recruiting
- HIV Infections
- Cabotegravir IR Formulation (reference)
- +2 more
- (no location specified)
Mar 8, 2023
Asthma Trial (Salbutamol HFA-152a, Salbutamol HFA-134a)
Not yet recruiting
- Asthma
- Salbutamol HFA-152a
- Salbutamol HFA-134a
- (no location specified)
Mar 17, 2023
HIV Trial in Las Vegas (Cabotegravir 200 mg/mL, Cabotegravir 400 mg/mL, Recombinant human hyaluronidase PH20 (rHuPH20))
Recruiting
- HIV Infections
- Cabotegravir 200 mg/mL
- +2 more
-
Orlando, Florida
- +3 more
Dec 1, 2022
HIV Trial in Canada, United States (CAB LA, RPV LA, RPV)
Active, not recruiting
- HIV Infections
- CAB LA
- +3 more
-
Phoenix, Arizona
- +29 more
Jan 22, 2023
Arthritis, Rheumatoid Trial (Otilimab)
Not yet recruiting
- Arthritis, Rheumatoid
- Otilimab
- (no location specified)
Mar 22, 2022
Human Immunodeficiency Virus Type 1 (HIV-1) Trial in Worldwide (Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine -
Active, not recruiting
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Cabotegravir - Injectable Suspension (CAB LA)
- Rilpivirine - Injectable Suspension (RPV LA)
-
Macon, Georgia
- +29 more
May 31, 2023
Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (GSK744, GSK744 LA, TMC278 LA)
Active, not recruiting
- Infection, Human Immunodeficiency Virus
- HIV Infections
- GSK744
- +4 more
-
Birmingham, Alabama
- +49 more
Dec 26, 2022
T-Cell Lymphoma Trial (Brentuximab vedotin)
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- (no location specified)
Jun 30, 2022
Multiple Myeloma Trial in Beijing, Jiang Su Province (Belantamab mafodotin)
Completed
- Multiple Myeloma
- Belantamab mafodotin
-
Beijing, China
- +2 more
Feb 8, 2022
Lymphocyte Count and High Fluorescent Count Correlate With Liver
Recruiting
- Dengue Fever
- Blood and Liver Function test
-
Sukoharjo, Central Java, Indonesia
- +1 more
Jun 1, 2022